For the year ending 2025-12-31, ACRS had -$4,610K decrease in cash & cash equivalents over the period. -$47,224K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -64,923 |
| Depreciation and amortization | 454 |
| Stock-based compensation expense | 12,384 |
| Revaluation of contingent consideration | 2,300 |
| Accounts receivable, prepaid expenses and other assets | -6,138 |
| Accounts payable | 8,447 |
| Accrued expenses and other liabilities | -8,097 |
| Deferred income | -3,816 |
| Net cash used in operating activities | -47,113 |
| Purchases of property and equipment | 111 |
| Purchases of marketable securities | 39,732 |
| Proceeds from sales and maturities of marketable securities | 89,041 |
| Payments of deferred transaction consideration for in-licensed assets | 833 |
| Net cash provided by (used in) investing activities | 48,365 |
| Payments of deferred transaction consideration for in-licensed assets | 5,416 |
| Payments of employee withholding taxes related to restricted stock unit award vesting | 446 |
| Net cash (used in) provided by financing activities | -5,862 |
| Net decrease in cash and cash equivalents | -4,610 |
| Cash and cash equivalents at beginning of period | 24,570 |
| Cash and cash equivalents at end of period | 19,960 |
Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, Inc. (ACRS)